| Human IL-18BP Protein (LTP10472) |
| LTP10472 |
| 100ug |
|
$203 In stock |
| Cytokines were the first modern immunotherapies to produce durable responses in patients with advanced cancer,components of the interleukin-18 (IL-18) pathway are upregulated on tumour-infiltrating lymphocytes, suggesting that IL-18 therapy could enhance anti-tumour immunity. IL-18BP, a high-affinity IL-18 decoy receptor, is frequently upregulated in diverse human and mouse tumours and limits the anti-tumour activity of IL-18 in mice. |
| Recombinant Human IL-18BP Protein is expressed from Expi293 with hFc tag at the C-terminal. It contains Thr31-Gly194. |
| IL-18BP |
| Human |
| O95998-2 |
| Thr31-Gly194 |
| The protein has a predicted MW of 44.4 kDa. Due to glycosylation, the protein migrates to 60-80 kDa based on the Tris-Bis PAGE result. |
| Immobilized Human IL-18 at 5ug/ml (100ul/Well) on the plate. Dose response curve for Human IL-18BP, hFc Tag with the EC50 of 18.2ng/ml determined by ELISA (QC Test). The affinity constant of 0.04nM as determined in SPR assay (Biacore T200). See testing image for detail. |
| C-hFc |
| Expi293 |
| > 95% as determined by Tris-Bis PAGE; > 95% as determined by HPLC |
| Less than 1EU per ug by the LAL method. |
| Lyophilized from 0.22 um filtered solution in PBS (pH 7.4). Normally 5% trehalose is added as a protectant before lyophilization. |
| Reconstituted protein stable at -80 C for 12 months, 4 C for 1 week. Use a manual defrost freezer and avoid repeated freeze-thaw cycles. |
| Shipped at ambient temperature. |
| Centrifuge tubes before opening. Reconstituting to a concentration of more than 100 ug/ml is recommended. Dissolve the lyophilized protein in distilled water. |
| |